secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001785530-21-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q3 net loss $13.8M; cash $170.4M; Merck collaboration for WTX-124
--------------------------------------------------------------------------------

- Net loss of $13.8M versus $6.1M in Q3 2020; R&D expenses $9.8M, G&A $4.0M.
- Cash and equivalents $170.4M, up from $92.6M at year-end 2020; runway through Q2 2023.
- Entered clinical trial collaboration with Merck to evaluate WTX-124 + KEYTRUDA in solid tumors.
- On track to file INDs for WTX-124 and WTX-330 in first half of 2022.
- Appointed Meeta Chatterjee, Ph.D., to board of directors in October 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/0001785530-21-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/howl-20211110.htm
  HTML page:      https://secwatch.observer/filing/0001785530-21-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer